¼¼°èÀÇ ÀΰøÀÓ½ÅÁßÀý¾à ½ÃÀå º¸°í¼­(2025³â)
Abortion Drugs Global Market Report 2025
»óǰÄÚµå : 1764229
¸®¼­Ä¡»ç : The Business Research Company
¹ßÇàÀÏ : On Demand Report
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 175 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,490 £Ü 6,253,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,490 £Ü 9,039,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,490 £Ü 11,824,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

ÀΰøÀÓ½ÅÁßÀý¾à ½ÃÀå ±Ô¸ð´Â ÇâÈÄ ¼ö³â°£ ±Þ¼ºÀåÇÒ °ÍÀ¸·Î Àü¸ÁµË´Ï´Ù. 2029³â¿¡´Â CAGR 11.3%·Î ¼ºÀåÇÒ Àü¸ÁÀ̸ç, 493¾ï 7,000¸¸ ´Þ·¯·Î ¼ºÀåÀÌ ¿¹ÃøµË´Ï´Ù. ¿¹Ãø ±â°£ µ¿¾È Àü¸ÁµÇ´Â ¼ºÀåÀº ¿ø°ÝÀÇ·á ¼­ºñ½º È®´ë, ÀÚÀ¯ÁÖÀÇ Áö¿ª¿¡¼­ÀÇ Á¤ºÎÁö¿ø Áõ°¡, ¿©¼º°Ç°­°ú °ü·ÃµÈ ½ÅÈï±â¾÷¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡, ÀÚ±â°ü¸®¸¦ ÅëÇÑ ÀΰøÀÓ½ÅÁßÀý ¼ö¿ë È®´ë, ÇコÄɾîÀÇ µðÁöÅÐÈ­ ÁøÀü µî¿¡ ±âÀÎÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ÀÌ ±â°£¿¡ ¿¹»óµÇ´Â ÁÖ¿ä µ¿ÇâÀ¸·Î´Â ¾à¹° Àü´Þ ±â¼ú Çõ½Å, µðÁöÅÐ ¹èÇÕ Ç÷§Æû ´ëµÎ, AI ÁÖµµ ¿ø°Ý »ó´ã µµ±¸, ÀÓ½ÅÁßÀý Äɾ À§ÇÑ ¸ð¹ÙÀÏ Çコ ¾ÖÇø®ÄÉÀ̼Ç, ÀÓ½ÅÁßÀý ÈÄ ¸ð´ÏÅ͸µÀ» À§ÇÑ ¿þ¾î·¯ºí ±â¼ú µîÀÌ ÀÖ½À´Ï´Ù.

¿¹±âÄ¡ ¾ÊÀº ÀӽŠÁõ°¡´Â ÇâÈÄ ¼ö³â°£ ÀΰøÀÓ½ÅÁßÀý¾à ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. °èȹ ¿Ü ÀÓ½ÅÀ̶õ ÀӽŠ½Ã Àǵµ³ª °èȹ ¾øÀÌ ¹ß»ýÇÏ´Â ÀÓ½ÅÀ» ¸»Çϸç, ´ëºÎºÐÀÇ °æ¿ì ÇÇÀÓµµ±¸ÀÇ Àϰü¼º ¾ø´Â »ç¿ëÀ̳ª À߸øµÈ »ç¿ëÀ¸·Î ÀÎÇÑ °ÍÀÔ´Ï´Ù. ÀÌ·¯ÇÑ Áõ°¡´Â ÇÇÀÓ¿¡ ´ëÇÑ Á¢±ÙÀÌ Á¦ÇÑµÈ °ÍÀÌ ÁÖ¿ä ¿øÀÎÀ̸ç, ºñ¿ë, ±³À° ºÎÁ·, ºÒÃæºÐÇÑ ÇコÄɾî ÀÎÇÁ¶ó µîÀÇ À庮ÀÌ È¿°úÀûÀÎ ÇÇÀÓ »ç¿ëÀ» ¹æÇØÇϰí ÀÖ½À´Ï´Ù. ÀΰøÀÓ½ÅÁßÀý¾àÀº °èȹµÇÁö ¾ÊÀº ÀÓ½ÅÀ» °ü¸®Çϱâ À§ÇÑ ¾ÈÀüÇÏ°í ºñ¿Ü°úÀûÀÎ ÇØ°áÃ¥À» Á¦°øÇϰí, °³ÀÎÀÇ »ý½Ä¿¡ °üÇÑ ÀÚÀ²¼ºÀ» ³ôÀ̸ç, ħ½ÀÀûÀΠóġÀÇ Çʿ伺À» ÃÖ¼ÒÈ­Çϸç, ÀÓ»ó°ú °¡Á¤ ¸ðµÎ¿¡¼­ ½Ã±âÀûÀýÇÑ ÀÇ·á Á¢±ÙÀ» È®º¸ÇÕ´Ï´Ù. ¿¹¸¦ µé¾î 2022³â 3¿ù À¯¿£Àα¸±â±Ý(UNFPA)Àº Àü ¼¼°è Àüü ÀÓ½ÅÀÇ ¾à Àý¹Ý, ¿¬°£ ¾à 1¾ï 2,100¸¸ ¸íÀÌ °èȹ ¿Ü ÀÓ½ÅÀ̶ó°í º¸°íÇß½À´Ï´Ù. ÀÌó·³ °èȹ ¹ÛÀÇ ÀӽŠÁõ°¡°¡ ÀΰøÀÓ½ÅÁßÀý¾à ½ÃÀå È®´ë¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù.

ÀΰøÀÓ½ÅÁßÀý¾à ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷Àº ȯÀÚ¸¦ À§ÇÑ ÇÕ¸®ÀûÀÎ °¡°Ý°ú °¡¿ë¼ºÀ» ³ôÀ̱â À§ÇØ Ç츶º£ÀÌÆ®ÀÇ ÀÏ¹Ý ¹öÀü°ú °°Àº Çõ½ÅÀûÀÎ Á¦Ç° °³¹ßÀ» ¼±È£ÇÕ´Ï´Ù. Ç츶º£ÀÌÆ® Á¦³×¸¯ ÀǾàǰÀº Àڱà ¼öÃàÀ» À¯¹ßÇϱâ À§ÇØ »ç¿ëµÇ´Â Ç츶º£ÀÌÆ® ¼±¹ßǰÀ» ´ëüÇÏ´Â Àúºñ¿ë ÀǾàǰÀÔ´Ï´Ù. »êÈÄ ÃâÇ÷ °ü¸®¿¡ È¿°úÀûÀÌ¸ç ¾ÈÀüÇϰí È¿À²ÀûÀÎ ¾àÀ» ÅëÇÑ ÀΰøÀÓ½ÅÁßÀýÀ» µµ¿ÍÁÝ´Ï´Ù. ¿¹¸¦ µé¾î, ¹Ì±¹ Á¦¾àȸ»çÀÎ ·Õ±×·Îºê ÆÄ¸¶½´Æ¼Äýº LLC´Â 2022³â 11¿ù ÀڱþÖÅä´Ï·Î ÀÎÇÑ »êÈÄÃâÇ÷À» Ä¡·áÇϱâ À§ÇÑ º¸´Ù Àú·ÅÇÏ°í ±¸Çϱ⠽¬¿î ¼±ÅÃÁö·Î Pfizer»çÀÇ Ç츶º£ÀÌÆ® Á¦³×¸¯ ÀǾàǰÀÎ Ä«º¸ÇÁ·Î½ºÆ® Æ®·Î¸ÞŸ¹Î ÁÖ»çÁ¦¸¦ Ãâ½ÃÇß½À´Ï´Ù. ÀÌ ¾àÀº ¶ÇÇÑ Àڱà ¼öÃà¿¡ ÀÇÇÑ ÀÓ½ÅÁßÀý °úÁ¤À» ¾ÈÀüÇÏ°Ô ÃËÁøÇÔÀ¸·Î½á ¾à¿¡ ÀÇÇÑ ÀÓ½ÅÁßÀý¿¡¼­µµ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¦³×¸¯ ÀǾàǰÀÇ ¹ß¸Å´Â, ƯÈ÷ ¼±¹ß ÀǾàǰÀÇ °¡°ÝÀ̳ª ÀÔ¼ö °¡´É¼º¿¡ °úÁ¦¸¦ ¾È°í ÀÖ´Â Áö¿ª¿¡¼­, ÇコÄÉ¾î ºñ¿ëÀ» »è°¨ÇØ, ÇÊ¿ä ºÒ°¡°áÇÑ ÀΰøÀÓ½ÅÁßÀý ÀÇ·á¿¡ ´ëÇÑ ¾×¼¼½º¸¦ °³¼±ÇÏ´Â µ¥ Áß¿äÇÑ ÇÑ °ÉÀ½ÀÌ µË´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå Æ¯Â¡

Á¦3Àå ½ÃÀå µ¿Çâ ¹× Àü·«

Á¦4Àå ½ÃÀå : ±Ý¸®, ÀÎÇ÷¹À̼Ç, ÁöÁ¤ÇÐ, ¹«¿ªÀüÀï ¹× °ü¼¼, Äڷγª ¹× ȸº¹ÀÌ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Æ÷ÇÔÇÑ °Å½Ã°æÁ¦ ½Ã³ª¸®¿À

Á¦5Àå ¼¼°èÀÇ ¼ºÀå ºÐ¼® ¹× Àü·« ºÐ¼® ÇÁ·¹ÀÓ¿öÅ©

Á¦6Àå ½ÃÀå ¼¼ºÐÈ­

Á¦7Àå Áö¿ªº° ¹× ±¹°¡º° ºÐ¼®

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå

Á¦9Àå Áß±¹ ½ÃÀå

Á¦10Àå Àεµ ½ÃÀå

Á¦11Àå ÀϺ» ½ÃÀå

Á¦12Àå È£ÁÖ ½ÃÀå

Á¦13Àå Àεµ³×½Ã¾Æ ½ÃÀå

Á¦14Àå Çѱ¹ ½ÃÀå

Á¦15Àå ¼­À¯·´ ½ÃÀå

Á¦16Àå ¿µ±¹ ½ÃÀå

Á¦17Àå µ¶ÀÏ ½ÃÀå

Á¦18Àå ÇÁ¶û½º ½ÃÀå

Á¦19Àå ÀÌÅ»¸®¾Æ ½ÃÀå

Á¦20Àå ½ºÆäÀÎ ½ÃÀå

Á¦21Àå µ¿À¯·´ ½ÃÀå

Á¦22Àå ·¯½Ã¾Æ ½ÃÀå

Á¦23Àå ºÏ¹Ì ½ÃÀå

Á¦24Àå ¹Ì±¹ ½ÃÀå

Á¦25Àå ij³ª´Ù ½ÃÀå

Á¦26Àå ³²¹Ì ½ÃÀå

Á¦27Àå ºê¶óÁú ½ÃÀå

Á¦28Àå Áßµ¿ ½ÃÀå

Á¦29Àå ¾ÆÇÁ¸®Ä« ½ÃÀå

Á¦30Àå °æÀï ±¸µµ ¹× ±â¾÷ ÇÁ·ÎÆÄÀÏ

Á¦31Àå ±âŸ ÁÖ¿ä ±â¾÷ ¹× Çõ½Å ±â¾÷

Á¦32Àå ¼¼°è ½ÃÀå °æÀï º¥Ä¡¸¶Å· ¹× ´ë½Ãº¸µå

Á¦33Àå ÁÖ¿ä ÀμöÇÕº´(M&A)

Á¦34Àå ÃÖ±Ù ½ÃÀå µ¿Çâ

Á¦35Àå ½ÃÀåÀÇ ÀáÀç·ÂÀÌ ³ôÀº ±¹°¡, ºÎ¹® ¹× Àü·«

Á¦36Àå ºÎ·Ï

AJY
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Abortion drugs are medications that end a pregnancy by triggering a process similar to a natural miscarriage. They are generally used during the first 10 weeks of pregnancy and are approved in many countries as a safe and effective method for abortion.

The primary categories of abortion drugs include mifepristone, misoprostol, pitocin, hemabate, carboprost, among others. Mifepristone is taken orally and works by blocking the hormone progesterone, leading to the breakdown of the uterine lining and ending early pregnancy. These medications can be administered through oral, intravenous, or subcutaneous routes. They are used for therapeutic purposes such as medical and surgical abortion. The drugs are distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

The abortion drugs market research report is one of a series of new reports from The Business Research Company that provides abortion drugs market statistics, including abortion drugs industry global market size, regional shares, competitors with an abortion drugs market share, detailed abortion drugs market segments, market trends and opportunities, and any further data you may need to thrive in the abortion drugs industry. The abortion drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The abortion drugs market size has grown rapidly in recent years. It will grow from $28.79 billion in 2024 to $32.15 billion in 2025 at a compound annual growth rate (CAGR) of 11.7%. The growth during the historic period can be attributed to a rise in unintended pregnancies, increased awareness of reproductive rights, higher demand for non-surgical abortion methods, population growth and urbanization, and wider availability of generic formulations.

The abortion drugs market size is expected to see rapid growth in the next few years. It will grow to $49.37 billion in 2029 at a compound annual growth rate (CAGR) of 11.3%. The projected growth in the forecast period can be credited to the expansion of telehealth services, increased government support in liberal regions, rising investment in women's health startups, growing acceptance of self-managed abortions, and the advancement of healthcare digitization. Key trends expected during this period include innovations in drug delivery technologies, the rise of digital prescription platforms, AI-driven teleconsultation tools, mobile health applications for abortion care, and wearable technology for post-abortion monitoring.

The increasing occurrence of unplanned pregnancies is expected to drive the growth of the abortion drug market in the coming years. Unplanned pregnancies are those that occur without intent or planning at the time of conception, often due to inconsistent or incorrect use of contraceptives. This rise is largely attributed to limited access to contraception, with barriers such as cost, lack of education, and insufficient healthcare infrastructure hindering effective birth control use. Abortion drugs offer a safe, non-surgical solution to manage unplanned pregnancies, empowering individuals with greater reproductive autonomy, minimizing the need for invasive procedures, and ensuring timely healthcare access both in clinical and home settings. For example, in March 2022, the United Nations Population Fund (UNFPA) reported that nearly half of all pregnancies worldwide, around 121 million annually, are unplanned. Thus, the growing number of unplanned pregnancies is fueling the expansion of the abortion drug market.

Leading companies in the abortion drug market are prioritizing the development of innovative products, such as generic versions of hemabate, to enhance affordability and accessibility for patients. Generic hemabate is a lower-cost alternative to the original Hemabate drug, used to induce uterine contractions. It is effective in managing postpartum bleeding and supports safe and efficient medical abortions. For example, in November 2022, Long Grove Pharmaceuticals LLC, a US-based pharmaceutical company, introduced carboprost tromethamine injection, the generic equivalent of Pfizer's Hemabate, as a more affordable and accessible option for treating postpartum hemorrhage caused by uterine atony. This medication also plays a vital role in medical abortion by safely facilitating the termination process through uterine contractions. The launch of such generic alternatives marks an important step in reducing healthcare costs and improving access to essential abortion care, particularly in regions facing challenges with the affordability and availability of branded medications.

In March 2024, CVS Health Corp, a US-based pharmacy company, partnered with Walgreens Boots Alliance Inc. to start offering the abortion pill mifepristone in stores across various states. Through this collaboration, CVS and Walgreens seek to expand access to reproductive healthcare by making the medication available at numerous retail locations, thereby supporting women's right to choose amid increasing legal limitations on abortion. Walgreens Boots Alliance Inc. is a US-based retail company that delivers pharmacy, health, and wellness products and services through its broad store network.

Major players in the abortion drugs market are Pfizer Inc., Bayer AG, Intas Pharmaceuticals, Sun Pharmaceutical Industries Ltd., Macleods Pharmaceuticals Ltd, Cipla Ltd., Lupin Ltd., Zydus Lifesciences Ltd., Cadila Pharmaceuticals, Alkem Laboratories Ltd., Shanghai Xinhua Pharmaceutical Co. Ltd., Medley Pharmaceuticals, Acme Formulations Ltd., Aristo Pharmaceuticals Pvt. Ltd., Mankind Pharma Ltd., Neiss Labs Ltd., Danco Laboratories LLC, GenBioPro Inc., Exelgyn SA, Linepharma International Limited, Adorshea.

North America was the largest region in the abortion drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in abortion drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the abortion drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The abortion drugs market consists of sales of prostaglandin analogs, anti-progestogens, anti-progestogens, non-steroidal anti-inflammatory drugs (NSAIDs), analgesics and sedatives. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Abortion Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on abortion drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for abortion drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The abortion drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Abortion Drugs Market Characteristics

3. Abortion Drugs Market Trends And Strategies

4. Abortion Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Abortion Drugs Growth Analysis And Strategic Analysis Framework

6. Abortion Drugs Market Segmentation

7. Abortion Drugs Market Regional And Country Analysis

8. Asia-Pacific Abortion Drugs Market

9. China Abortion Drugs Market

10. India Abortion Drugs Market

11. Japan Abortion Drugs Market

12. Australia Abortion Drugs Market

13. Indonesia Abortion Drugs Market

14. South Korea Abortion Drugs Market

15. Western Europe Abortion Drugs Market

16. UK Abortion Drugs Market

17. Germany Abortion Drugs Market

18. France Abortion Drugs Market

19. Italy Abortion Drugs Market

20. Spain Abortion Drugs Market

21. Eastern Europe Abortion Drugs Market

22. Russia Abortion Drugs Market

23. North America Abortion Drugs Market

24. USA Abortion Drugs Market

25. Canada Abortion Drugs Market

26. South America Abortion Drugs Market

27. Brazil Abortion Drugs Market

28. Middle East Abortion Drugs Market

29. Africa Abortion Drugs Market

30. Abortion Drugs Market Competitive Landscape And Company Profiles

31. Abortion Drugs Market Other Major And Innovative Companies

32. Global Abortion Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Abortion Drugs Market

34. Recent Developments In The Abortion Drugs Market

35. Abortion Drugs Market High Potential Countries, Segments and Strategies

36. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â